A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • Which information matters most? Transparency...
Publication - published on 02 Oct 2020

Which information matters most? Transparency by pharmaceutical companies that builds access to medicine plus trust and engagement

The world depends on the pharmaceutical industry for life-saving medicines and vaccines yet trust in the industry is low. Pharmaceutical companies have many opportunities to improve access to medicine – including by sharing specific information with research organisations, NGOs, governments, or the public. 

In this Viewpoint, Marijn Verhoef discusses why and when transparency by the pharma industry matters for access to medicine, and how the Access to Medicine Foundation enables transparency to improve. 

It covers:

  • Who is asking for transparency and how to ensure requests are reasonable
  • Access to medicine as a material issue for pharmaceutical companies
  • The main areas where improvement in transparency is needed to improve access to medicine
  • Transparency as a tool for other organisations working in the field
  • The direct benefits for pharmaceutical companies from greater transparency 
  • Enabling role of the Access to Medicine Foundation in targeting transparency improvements

 


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |